Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-03-2000 | Meeting abstract

Herceptin™ (trastuzumab) in patients who overexpress Her-2 and have failed multiple chemotherapy regimens for advanced breast cancer: a pragmatic study

Published in: Breast Cancer Research | Special Issue 1/2000

Login to get access

Excerpt

This prospective study will include patients who are at least 18 years of age, with a histologically or cytologically confirmed diagnosis of advanced breast cancer (ABC), who have failed or are resistant to treatment with at least two chemotherapy regimens for ABC, and who overexpress HER-2. A maximum of 62 patients are to be included for the detection of an overall response rate of 20% (10-30%, 95% confidence interval). …
Metadata
Title
Herceptin™ (trastuzumab) in patients who overexpress Her-2 and have failed multiple chemotherapy regimens for advanced breast cancer: a pragmatic study
Publication date
01-03-2000
Published in
Breast Cancer Research / Issue Special Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr108

Other articles of this Special Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Meeting abstract

The expression of the EGFR family members in breast carcinomas

Meeting abstract

Identification of two novel breast cancer associated genes by the differential display method

Meeting abstract

One test to identify 50% of all Norwegian BRCA1 mutations

Meeting abstract

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer

Meeting abstract

Screening for BRCA1 gene mutations by capillary electrophoretic REF-SSCP

Meeting abstract

Constitutional alterations of 9p23-24 in independent BRCA2 breast cancer families
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits